Cargando…
The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are improving the treatment of patients with non-small cell lung cancer. Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, fr...
Autores principales: | Murakami, Yuichi, Sonoda, Kahori, Abe, Hideyuki, Watari, Kosuke, Kusakabe, Daiki, Azuma, Koichi, Kawahara, Akihiko, Akiba, Jun, Oneyama, Chitose, Pachter, Jonathan A., Sakai, Kazuko, Nishio, Kazuto, Kuwano, Michihiko, Ono, Mayumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642590/ https://www.ncbi.nlm.nih.gov/pubmed/29050315 http://dx.doi.org/10.18632/oncotarget.19982 |
Ejemplares similares
-
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
por: Murakami, Yuichi, et al.
Publicado: (2022) -
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
por: Azuma, Koichi, et al.
Publicado: (2014) -
Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022) -
Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020) -
Roles of Raft-Anchored Adaptor Cbp/PAG1 in Spatial Regulation of c-Src Kinase
por: Saitou, Takashi, et al.
Publicado: (2014)